Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.




) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.1%. By the end of trading, Pfizer fell $0.32 (-1.1%) to $28.02 on light volume. Throughout the day, 20,017,011 shares of Pfizer exchanged hands as compared to its average daily volume of 57,511,000 shares. The stock ranged in price between $28.02-$28.37 after having opened the day at $28.33 as compared to the previous trading day's close of $28.34. Other companies within the Drugs industry that declined today were:

Mast Therapeutics



), down 40.6%,

Rigel Pharmaceuticals



), down 13.5%,

ANI Pharmaceuticals



Scroll to Continue

TheStreet Recommends

), down 9.1% and

Biosante Pharmaceuticals



), down 9.1%.

Pfizer Inc., a biopharmaceutical company, discovers, develops, manufactures, and sells medicines for people and animals worldwide. Pfizer has a market cap of $186.4 billion and is part of the health care sector. Shares are up 12.3% year to date as of the close of trading on Friday. Currently there are 10 analysts that rate Pfizer a buy, 1 analyst rates it a sell, and 3 rate it a hold.

TheStreet Ratings rates


as a


. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income and expanding profit margins. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.

On the positive front,

GW Pharmaceuticals PLC ADR



), up 18.8%,

Accelerate Diagnostics



), up 15.2%,

Biocryst Pharmaceuticals



), up 13.7% and

Ambit Biosciences



), up 12.2% , were all gainers within the drugs industry with

Onyx Pharmaceuticals



) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.